zoledronic acid

(redirected from Aclasta)
Also found in: Medical.

zoledronic acid, zoledronate

n ácido zoledrónico, zoledronato (esp. Esp)
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
In the search, we used the terms: (inflammatory bowel disease OR ulcerative colitis OR Crohn's disease) and (osteoporosis or osteopenia or (bone and (density or mass or loss))) and (exp Diphosphonates/or (bisphosphonate* or alendron* or fosamax or etidron* or didronel or risedron* or actonel or ibandron* or bonivaor zolendron* or zometa or zomera or aclasta or reclastor pamidron* or aredia)).
Alkaline phosphatase U/L Months 0 3 6 9 12 15 18 Calcitonin 15000 1400 1345 Aclasta 1345 500 215 170 125 Alkaline 80 80 80 80 80 80 80 Phosphatase (normal range) Note: Table made from line graph.
Mansoor Jaffari has the products Voltral ,Caflam, Ternelin, Aclasta and Miacalcic.
Primary care nurses at the Golden Bay Medical Centre in Takaka have been doing aclasta infusion for more than two years.
Doctors prescribing Zometa to block the return of tumors "should stop or at least question that practice." Zometa, given as an infusion, also is sold at a lower dose under the name Reclast or Aclasta to treat osteoporosis.
The HORIZON Pivotal Fracture Trial was funded by Novartis, which markets zoledronic acid (Aclasta).
Disclosures: The HORIZON Pivotal Fracture Trial was funded by Novartis, which markets zoledronic acid (Aclasta).
Bisphosphonates include Aclasta, Actonel, Aredia, Bondronat, Boniva, Didronel, Fosamax, Fosavance, Reclast, Skelid and Zometa.
18 October 2010 - Swiss Novartis (VTX: NOVN) said on Saturday that new six-year study results have confirmed the long-term efficacy and safety profile of Aclasta, taken once a year, for the treatment of osteoporosis in post-menopausal women.
Higher sales are also seen for such newer products as Lucentis for macular degeneration and Aclasta for osteoporosis.
The most recent is Aclasta, the first annual treatment for post-menopausal women, which reduced risk of hip fractures by 41 per cent in trials.